NEW YORK (GenomeWeb News) — NeoClone Biotechnology has received a $750,000 Phase II Small Business Innovation Research grant from the National Institutes of Health to help it continue developing an antibody microarray for ovarian cancer, the company said this week.
 
The funding, administered through the National Cancer Institute, will pay for continued research and new equipment and staff for its Madison, Wis., labs.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.

In Science this week: reduction in bee phylogenetic diversity, and more.

The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.

The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.